CoChat

PKA inhibits WNT signalling in adrenal cortex zonation and prevents malignant tumour development

Open access
Drelon, Coralie, Berthon, Annabel, Sahut-Barnola, Isabelle, Mathieu, Mickaël, Dumontet, Typhanie, Rodriguez, Stéphanie, Batisse-Lignier, Marie, Tabbal, Houda, Tauveron, Igor, Lefrançois-Martinez, Anne-Marie, Pointud, Jean-Christophe, Gomez-Sanchez, Celso E., Vainio, Seppo, Shan, Jingdong, Sacco, Sonia, Schedl, Andreas, Stratakis, Constantine A., Martinez, Antoine, Val, Pierre · 2016 · Nature Communications

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Adrenal cortex physiology relies on functional zonation, essential for production of aldosterone by outer zona glomerulosa (ZG) and glucocorticoids by inner zona fasciculata (ZF). The cortex undergoes constant cell renewal, involving recruitment of subcapsular progenitors to ZG fate and subsequent lineage conversion to ZF identity. Here we show that WNT4 is an important driver of WNT pathway activation and subsequent ZG differentiation and demonstrate that PKA activation prevents ZG differentiation through WNT4 repression and WNT pathway inhibition. This suggests that PKA activation in ZF is a key driver of WNT inhibition and lineage conversion. Furthermore, we provide evidence that constitutive PKA activation inhibits, whereas partial inactivation of PKA catalytic activity stimulates β-catenin-induced tumorigenesis. Together, both lower PKA activity and higher WNT pathway activity lead to poorer prognosis in adrenocortical carcinoma (ACC) patients. These observations suggest that PKA acts as a tumour suppressor in the adrenal cortex, through repression of WNT signalling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms12751

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Antagonistic effects of PKA on WNT signalling and ZG differentiation. (a) ACTH treatment inhibits WNT target genes expression in the adrenal gland. Wild-type C57/Bl6 mice were treated for 5 days with vehicle (Ctrl) or Dexamethasone (Dex) or for 3 days with dexamethasone followed by 2 days of Synacthene retard (Dex+ACTH). Lef1 and Axin2 expression levels were then analysed by RT–qPCR on mRNAs extracted from the adrenals. Bars represent mean expression in four animals per group±s.e.m. (b) WNT pathway and ZG differentiation are inhibited by ACTH treatment. Expression of β-catenin, LEF1 (WNT pathway), AKR1B7 (ZF) and CYP11B2 (ZG) was analysed by immunohistochemistry in the adrenals from the same animal groups as in a. (c) Constitutive activation of PKA signalling inhibits WNT target genes expression in the adrenal gland. Axin2 and Lef1 expression levels were analysed by RT–qPCR on mRNAs extracted from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. (d) Constitutive activation of PKA signalling inhibits β-catenin and LEF1 accumulation in ZG. Expression of β-catenin and LEF1 was analysed by immunohistochemistry in the adrenals from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. (e) ZG differentiation is inhibited by constitutive PKA signalling. Cyp11b2 and angiotensin II receptor AT1R isoforms a and b expression levels were analysed by RT–qPCR on mRNAs extracted from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. (f) Constitutive PKA signalling promotes ZF differentiation at the expense of ZG. Expression of CYP11B2 and AKR1B7 was analysed by immunohistochemistry in the adrenals from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. In c,e, bars represent mean expression in six animals per group±s.e.m. Statistical analyses were conducted by one-way ANOVA followed by Tukey's post hoc test (a) or by Student's t-test (c,e). *P<0.05; **P<0.005; ***P<0.0005; NS, not significant. In all the images, insets are focused on ZG. Scale bars, 100 μm. M, medulla; ZG, zona glomerulosa; ZF, zona fasciculata.
Figure 1 Antagonistic effects of PKA on WNT signalling and ZG differentiation. (a) ACTH treatment inhibits WNT target genes expression in the adrenal gland. Wild-type C57/Bl6 mice were treated for 5 days with vehicle (Ctrl) or Dexamethasone (Dex) or for 3 days with dexamethasone followed by 2 days of Synacthene retard (Dex+ACTH). Lef1 and Axin2 expression levels were then analysed by RT–qPCR on mRNAs extracted from the adrenals. Bars represent mean expression in four animals per group±s.e.m. (b) WNT pathway and ZG differentiation are inhibited by ACTH treatment. Expression of β-catenin, LEF1 (WNT pathway), AKR1B7 (ZF) and CYP11B2 (ZG) was analysed by immunohistochemistry in the adrenals from the same animal groups as in a. (c) Constitutive activation of PKA signalling inhibits WNT target genes expression in the adrenal gland. Axin2 and Lef1 expression levels were analysed by RT–qPCR on mRNAs extracted from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. (d) Constitutive activation of PKA signalling inhibits β-catenin and LEF1 accumulation in ZG. Expression of β-catenin and LEF1 was analysed by immunohistochemistry in the adrenals from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. (e) ZG differentiation is inhibited by constitutive PKA signalling. Cyp11b2 and angiotensin II receptor AT1R isoforms a and b expression levels were analysed by RT–qPCR on mRNAs extracted from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. (f) Constitutive PKA signalling promotes ZF differentiation at the expense of ZG. Expression of CYP11B2 and AKR1B7 was analysed by immunohistochemistry in the adrenals from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. In c,e, bars represent mean expression in six animals per group±s.e.m. Statistical analyses were conducted by one-way ANOVA followed by Tukey's post hoc test (a) or by Student's t-test (c,e). *P<0.05; **P<0.005; ***P<0.0005; NS, not significant. In all the images, insets are focused on ZG. Scale bars, 100 μm. M, medulla; ZG, zona glomerulosa; ZF, zona fasciculata.CC BY · PubMed Central
Figure 2 Effect of PKA activation on downstream WNT pathway phosphorylation. (a) Forskolin represses AXIN2 expression in human adrenocortical H295R cells. Human H295R cells were treated with either vehicle (0, DMSO) or Forskolin 10−5 M (Fsk) for 1 to 24 h and AXIN2 expression was analysed by RT–qPCR. Bars represent mean expression in at least three independent experiments (in triplicate)±s.e.m. Statistical analyses were performed by one-way ANOVA followed by Dunnett's multiple comparison test. (b) Forskolin activates AXIN2 expression in COS7 cells. COS7 cells were treated with Forskolin for 1 to 24 h and AXIN2 expression was analysed as described in a. (c) Differential phosphorylation of β-catenin and GSK3β in COS7 and H295R cells. COS7 and H295R cells were treated as in a. Proteins were extracted and subjected to western blot analysis with antibodies to phospho/dephospho-β-catenin, phospho-GSK3β or the corresponding total proteins. β-catenin phosphorylations/dephosphorylations were sorted as activating (pS552, pS675, active beta-catenin) and inactivating (pT41/S45 and pS33/S37/T41). GSK3β serine 9 phosphorylation (pS9) results in its inactivation. GSK3β tyrosine 216 phosphorylation (pY216) results in its activation. Phospho-GSK3 antibodies recognize phospho-GSK3β arrowheads, and phospho-GSK3α (top band) (d) Phosphorylation of β-catenin and GSK3β in response to constitutive PKA activation in vivo. Activating and inactivating phosphorylations of β-catenin and Gsk3β were analysed in adrenal protein extracts from four wild-type and 4 Sf1:Cre;Prkar1Fl/Fl mice as described in c. (e) Constitutive activation of PKA inhibits activating phosphorylations and stimulates inactivating phosphorylations in vivo. Graphs show pooled quantification of phospho-specific signals in d and Supplementary Fig. 3, representing a total of nine wild-type and nine Sf1:Cre;Prkar1aFl/Fl mice. These were normalized to quantification of total corresponding proteins. Statistical analyses were performed with Student's t-test. *P<0.05; ***P<0.0005; NS, not significant.
Figure 2 Effect of PKA activation on downstream WNT pathway phosphorylation. (a) Forskolin represses AXIN2 expression in human adrenocortical H295R cells. Human H295R cells were treated with either vehicle (0, DMSO) or Forskolin 10−5 M (Fsk) for 1 to 24 h and AXIN2 expression was analysed by RT–qPCR. Bars represent mean expression in at least three independent experiments (in triplicate)±s.e.m. Statistical analyses were performed by one-way ANOVA followed by Dunnett's multiple comparison test. (b) Forskolin activates AXIN2 expression in COS7 cells. COS7 cells were treated with Forskolin for 1 to 24 h and AXIN2 expression was analysed as described in a. (c) Differential phosphorylation of β-catenin and GSK3β in COS7 and H295R cells. COS7 and H295R cells were treated as in a. Proteins were extracted and subjected to western blot analysis with antibodies to phospho/dephospho-β-catenin, phospho-GSK3β or the corresponding total proteins. β-catenin phosphorylations/dephosphorylations were sorted as activating (pS552, pS675, active beta-catenin) and inactivating (pT41/S45 and pS33/S37/T41). GSK3β serine 9 phosphorylation (pS9) results in its inactivation. GSK3β tyrosine 216 phosphorylation (pY216) results in its activation. Phospho-GSK3 antibodies recognize phospho-GSK3β arrowheads, and phospho-GSK3α (top band) (d) Phosphorylation of β-catenin and GSK3β in response to constitutive PKA activation in vivo. Activating and inactivating phosphorylations of β-catenin and Gsk3β were analysed in adrenal protein extracts from four wild-type and 4 Sf1:Cre;Prkar1Fl/Fl mice as described in c. (e) Constitutive activation of PKA inhibits activating phosphorylations and stimulates inactivating phosphorylations in vivo. Graphs show pooled quantification of phospho-specific signals in d and Supplementary Fig. 3, representing a total of nine wild-type and nine Sf1:Cre;Prkar1aFl/Fl mice. These were normalized to quantification of total corresponding proteins. Statistical analyses were performed with Student's t-test. *P<0.05; ***P<0.0005; NS, not significant.CC BY · PubMed Central
Figure 3 WNT4 is downregulated by PKA signalling activation. (a) Constitutive activation of PKA signalling inhibits ZG markers expression. Volcano plot shows differential gene expression in adrenals from four Sf1:Cre;Prakr1aFl/Fl mice compared with four wild-type littermates. A number of ZG differentiation markers (gene symbols in blue) are among the most significantly downregulated genes. As expected, Prkar1a expression (red rectangle) is significantly decreased in knockouts. (b) Constitutive activation of PKA signalling modulates expression of WNT pathway target genes and regulators. Colour-coded heatmap shows expression of the 15 genes that were significantly deregulated (adjusted P value <0.05). (c) Expression of NDRG1, CDC73 and WNT4 in mouse adrenals. Expression of the two potential WNT signalling repressors NDRG1 and CDC73 and of the WNT ligand WNT4 was analysed by immunohistochemistry in wild-type (n=4; a,c,e) and Sf1:Cre;Prkar1aFl/Fl adrenals (n=4; b,d,f). Hoechst nuclear staining in c and d highlights the lack of Cdc73 expression in wild-type outer cortex. Insets show high magnification pictures of ZG. Arrowheads show adrenal capsule. (d) Constitutive activation of PKA signalling inhibits Wnt4 expression. Wnt4 expression levels were analysed by RT–qPCR on mRNAs extracted from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. Bars represent the mean expression in six animals per group±s.e.m. Statistical analyses were performed by Student's t-test. (e) ACTH stimulation represses Wnt4 expression. Wnt4 expression levels were analysed by RT–qPCR on mRNAs extracted from adrenals of wild-type mice treated with vehicle, dexamethasone or dexamethasone and ACTH as in Fig. 1a. Bars represent the mean expression in four animals per group±s.e.m. Statistical analyses were performed by one-way ANOVA followed by Tukey's post hoc test. (f) ACTH induces a rapid decrease in WNT4 protein accumulation. WNT4 expression was analysed by immunohistochemistry in the adrenal cortex of wild-type mice (n=4), 24 h after a single ACTH (Synacthene retard) injection. *P<0.05; **P<0.005. Scale bars, 100 μm.
Figure 3 WNT4 is downregulated by PKA signalling activation. (a) Constitutive activation of PKA signalling inhibits ZG markers expression. Volcano plot shows differential gene expression in adrenals from four Sf1:Cre;Prakr1aFl/Fl mice compared with four wild-type littermates. A number of ZG differentiation markers (gene symbols in blue) are among the most significantly downregulated genes. As expected, Prkar1a expression (red rectangle) is significantly decreased in knockouts. (b) Constitutive activation of PKA signalling modulates expression of WNT pathway target genes and regulators. Colour-coded heatmap shows expression of the 15 genes that were significantly deregulated (adjusted P value <0.05). (c) Expression of NDRG1, CDC73 and WNT4 in mouse adrenals. Expression of the two potential WNT signalling repressors NDRG1 and CDC73 and of the WNT ligand WNT4 was analysed by immunohistochemistry in wild-type (n=4; a,c,e) and Sf1:Cre;Prkar1aFl/Fl adrenals (n=4; b,d,f). Hoechst nuclear staining in c and d highlights the lack of Cdc73 expression in wild-type outer cortex. Insets show high magnification pictures of ZG. Arrowheads show adrenal capsule. (d) Constitutive activation of PKA signalling inhibits Wnt4 expression. Wnt4 expression levels were analysed by RT–qPCR on mRNAs extracted from wild-type and Sf1:Cre;Prkar1aFl/Fl adrenals. Bars represent the mean expression in six animals per group±s.e.m. Statistical analyses were performed by Student's t-test. (e) ACTH stimulation represses Wnt4 expression. Wnt4 expression levels were analysed by RT–qPCR on mRNAs extracted from adrenals of wild-type mice treated with vehicle, dexamethasone or dexamethasone and ACTH as in Fig. 1a. Bars represent the mean expression in four animals per group±s.e.m. Statistical analyses were performed by one-way ANOVA followed by Tukey's post hoc test. (f) ACTH induces a rapid decrease in WNT4 protein accumulation. WNT4 expression was analysed by immunohistochemistry in the adrenal cortex of wild-type mice (n=4), 24 h after a single ACTH (Synacthene retard) injection. *P<0.05; **P<0.005. Scale bars, 100 μm.CC BY · PubMed Central
Figure 4 WNT4 repression mediates the effect of PKA on WNT signalling in the adrenal gland. (a) Forskolin represses WNT4 expression in human adrenocortical H295R cells. Human H295R cells were treated with either vehicle (0) or Forskolin 10−5M (Fsk) for 1 to 24 h and WNT4 expression was analysed by RTqPCR. Bars represent mean expression in three independent experiments (in triplicate)±s.e.m. (b) AXIN2 and WNT4 expression levels are correlated in H295R cells. AXIN2 and WNT4 expression levels were correlated on the basis of RTqPCR data generated from H295R cell treatments. (c) Overexpression of WNT4 reverses the effect of Forskolin on AXIN2 expression. H295R cells were transfected with pCMV-WNT4 to induce overexpression of WNT4 and treated with DMSO or Forskolin 10−5M (Fsk) for 8 h. Expression of AXIN2 was determined by RTqPCR. Bars represent mean expression in three independent experiments±s.e.m. Statistical analyses were performed by one-way ANOVA followed by Tukey's post-hoc test (d) Wnt4 genetic ablation inhibits WNT pathway activation in ZG. Expression of β-catenin and WNT pathway target LEF1 was analysed by immunohistochemistry in the adrenals from wild-type and Sf1:Cre;Wnt4Fl/Fl mice. (e) Wnt4 genetic ablation is associated with decreased Axin2 and Lef1 expression in the adrenal. Axin2 and Lef1 expression levels were analysed by RTqPCR on mRNAs extracted from wild-type and Sf1:Cre;Wnt4Fl/Fl adrenals. Bars represent the mean expression in 5 animals per group±s.e.m. Statistical analyses were performed by Student's t test. (f) Wnt4 genetic ablation is associated with loss of ZG differentiation and expansion of ZF. Expression of CYP11B2 (ZG) and AKR1B7 (ZF) was analysed in the adrenals from wild-type and Sf1:Cre;Wnt4Fl/Fl mice. (g) The ability of ACTH to repress Axin2 and Lef1 expression is blunted in Wnt4 knockout adrenals. Wild-type and Sf1:Cre;Wnt4Fl/Fl mice were treated for three days with PBS or ACTH (Synacthene Retard) and Axin2 and Lef1 expression levels were evaluated by RTqPCR. Bars represent the mean expression in 5 adrenals per genotype and per treatment group±s.e.m. Fold repression by ACTH over PBS in both wild-type and Sf1:Cre;Wnt4Fl/Fl mice is shown. Statistical analyses were performed by Student's t test. *P<0.05; **P<0.005; ***P<0.0005; NS: Not significant. Scale bars, 100 μm. ZG, zona glomerulosa; ZF, zona fasciculata; M, medulla.
Figure 4 WNT4 repression mediates the effect of PKA on WNT signalling in the adrenal gland. (a) Forskolin represses WNT4 expression in human adrenocortical H295R cells. Human H295R cells were treated with either vehicle (0) or Forskolin 10−5M (Fsk) for 1 to 24 h and WNT4 expression was analysed by RTqPCR. Bars represent mean expression in three independent experiments (in triplicate)±s.e.m. (b) AXIN2 and WNT4 expression levels are correlated in H295R cells. AXIN2 and WNT4 expression levels were correlated on the basis of RTqPCR data generated from H295R cell treatments. (c) Overexpression of WNT4 reverses the effect of Forskolin on AXIN2 expression. H295R cells were transfected with pCMV-WNT4 to induce overexpression of WNT4 and treated with DMSO or Forskolin 10−5M (Fsk) for 8 h. Expression of AXIN2 was determined by RTqPCR. Bars represent mean expression in three independent experiments±s.e.m. Statistical analyses were performed by one-way ANOVA followed by Tukey's post-hoc test (d) Wnt4 genetic ablation inhibits WNT pathway activation in ZG. Expression of β-catenin and WNT pathway target LEF1 was analysed by immunohistochemistry in the adrenals from wild-type and Sf1:Cre;Wnt4Fl/Fl mice. (e) Wnt4 genetic ablation is associated with decreased Axin2 and Lef1 expression in the adrenal. Axin2 and Lef1 expression levels were analysed by RTqPCR on mRNAs extracted from wild-type and Sf1:Cre;Wnt4Fl/Fl adrenals. Bars represent the mean expression in 5 animals per group±s.e.m. Statistical analyses were performed by Student's t test. (f) Wnt4 genetic ablation is associated with loss of ZG differentiation and expansion of ZF. Expression of CYP11B2 (ZG) and AKR1B7 (ZF) was analysed in the adrenals from wild-type and Sf1:Cre;Wnt4Fl/Fl mice. (g) The ability of ACTH to repress Axin2 and Lef1 expression is blunted in Wnt4 knockout adrenals. Wild-type and Sf1:Cre;Wnt4Fl/Fl mice were treated for three days with PBS or ACTH (Synacthene Retard) and Axin2 and Lef1 expression levels were evaluated by RTqPCR. Bars represent the mean expression in 5 adrenals per genotype and per treatment group±s.e.m. Fold repression by ACTH over PBS in both wild-type and Sf1:Cre;Wnt4Fl/Fl mice is shown. Statistical analyses were performed by Student's t test. *P<0.05; **P<0.005; ***P<0.0005; NS: Not significant. Scale bars, 100 μm. ZG, zona glomerulosa; ZF, zona fasciculata; M, medulla.CC BY · PubMed Central
Figure 5 Constitutive PKA signalling counteracts constitutive WNT signalling. (a,b) Constitutive PKA activation partially rescues WNT-induced developmental phenotypes. (a) Constitutive activation of β-catenin with Sf1:Cre driver is associated with right adrenal gland aplasia in 9 out of 14 animals (left bar). Genetic ablation of Prkar1a significantly rescues this phenotype (aplasia in two out of eight animals, right bar), P=0.0416 in N-1 two proportion test. (b) Left adrenal size (a) and histological features are partially restored by genetic ablation of Prkar1a in the context of Sf-1:Cre mediated constitutive activation of β-catenin (c versus b). Wild-type adrenal is shown in d. (c,d) Constitutive PKA activation inhibits WNT-induced proliferation. (c) Ki67 expression was analysed by immunohistochemistry in wild-type, constitutive active β-catenin mutants (ΔCat;Akr1b7:Cre) and constitutive active β-catenin mutants in the context of Prkar1a genetic ablation (ΔCat;Prkar1aFl/Fl;Akr1b7:Cre). (d) Ki67 positive cells were separately counted in the adrenal cortex and central adrenal region of 12–14 animals of each genotype. Numbers of positive cells are represented as a percentage of positive cells in each wild-type compartment. (e,f) Constitutive PKA activation inhibits WNT-induced ectopic ZG differentiation. (e) Expression of the ZG marker DAB2 (see Supplementary Fig. 6B) was analysed by immunohistochemistry in the same genotypes as in c. (f) DAB2 stained areas were measured separately in the adrenal cortex and central adrenal region of 10–15 animals of each genotype. Stained areas are expressed as a percentage of total adrenal surfaces. Statistical analyses in d,f were conducted by one-way ANOVA followed by Tukey's post hoc test *P<0.05; **P<0.005; ***P<0.0005; NS, not significant. Scale bars, 100 μm. Dashed lines delimit cortex from central adrenal area (medulla and ectopic glomerulosa cells).
Figure 5 Constitutive PKA signalling counteracts constitutive WNT signalling. (a,b) Constitutive PKA activation partially rescues WNT-induced developmental phenotypes. (a) Constitutive activation of β-catenin with Sf1:Cre driver is associated with right adrenal gland aplasia in 9 out of 14 animals (left bar). Genetic ablation of Prkar1a significantly rescues this phenotype (aplasia in two out of eight animals, right bar), P=0.0416 in N-1 two proportion test. (b) Left adrenal size (a) and histological features are partially restored by genetic ablation of Prkar1a in the context of Sf-1:Cre mediated constitutive activation of β-catenin (c versus b). Wild-type adrenal is shown in d. (c,d) Constitutive PKA activation inhibits WNT-induced proliferation. (c) Ki67 expression was analysed by immunohistochemistry in wild-type, constitutive active β-catenin mutants (ΔCat;Akr1b7:Cre) and constitutive active β-catenin mutants in the context of Prkar1a genetic ablation (ΔCat;Prkar1aFl/Fl;Akr1b7:Cre). (d) Ki67 positive cells were separately counted in the adrenal cortex and central adrenal region of 12–14 animals of each genotype. Numbers of positive cells are represented as a percentage of positive cells in each wild-type compartment. (e,f) Constitutive PKA activation inhibits WNT-induced ectopic ZG differentiation. (e) Expression of the ZG marker DAB2 (see Supplementary Fig. 6B) was analysed by immunohistochemistry in the same genotypes as in c. (f) DAB2 stained areas were measured separately in the adrenal cortex and central adrenal region of 10–15 animals of each genotype. Stained areas are expressed as a percentage of total adrenal surfaces. Statistical analyses in d,f were conducted by one-way ANOVA followed by Tukey's post hoc test *P<0.05; **P<0.005; ***P<0.0005; NS, not significant. Scale bars, 100 μm. Dashed lines delimit cortex from central adrenal area (medulla and ectopic glomerulosa cells).CC BY · PubMed Central
Figure 6 Prkaca heterozygosity accelerates WNT-induced tumorigenesis. (a) Adrenal weight is significantly increased by loss of one Prkaca allele. Adrenal glands from wild-type, ΔCat;Akr1b7:Cre and ΔCat;Prkaca+/−;Akr1b7:Cre mice were weighed on killing. (b) Prkaca heterozygosity accelerates WNT-induced hyperplasia and dysplasia. ΔCat;Akr1b7:Cre (a) and ΔCat;Prkaca+/−;Akr1b7:Cre (b–d) adrenals were counterstained with haematoxylin and eosin. Pictures in b–d represent the range of phenotypes resulting from Prkaca heterozygosity. Scale bar, 400 μm. (c,d) Prkaca heterozygosity increases proliferation. Ki67 positive cells were counted in five high-power fields per adrenal (WT, n=3; ΔCat;Akr1b7:Cre, n=4; ΔCat;Prkaca+/−;Akr1b7:Cre, n=9).Results are expressed as a labelling index. Pictures in d show high-power fields for one ΔCat;Akr1b7:Cre adrenal (a) and three different ΔCat;Prkaca+/−;Akr1b7:Cre adrenals (b–d). (e) Prkaca heterozygosity is associated with increased malignancy. VegfA and Cnxa43 expression levels were analysed by RT–qPCR in wild-type (n=5), ΔCat;Akr1b7:Cre (n=7) and ΔCat;Prkaca+/−;Akr1b7:Cre (n=12) adrenals. (f,g) Prkaca heterozygosity increases WNT pathway activity. (f) Axin2 and Lef1 expression levels were analysed by RT–qPCR (g) LEF1 expression was analysed by immunohistochemistry in ΔCat;Akr1b7:Cre and ΔCat;Prkaca+/−;Akr1b7:Cre adrenals. Insets show ectopic accumulation of LEF1 within ZF. Scale bar, 100 μm. (h) Low StAR expression is associated with lower overall survival in ACC patients. The patients were separated as two equivalent groups of high (n=39) and low (n=40) StAR expression. Left panel: Kaplan–Meier estimates of overall survival. Right panel: patients were ordered by cut-off-centred StAR expression. Dark grey boxes indicate specific death. (i) WNT pathway activity is inversely correlated with StAR expression in ACC patients. Adrenocortical carcinoma patients with no mutation in CTNNB1, APC and ZNRF3 were selected and a WNT pathway activation signature was established based on expression levels of LEF1, AXIN2 and APCDD1. Left panel: Spearman correlation between WNT signature and StAR expression. Right panel: hierarchical clustering of patients as a function of StAR expression and corresponding levels of WNT gene signature and individual WNT target genes expression. Bars in e,f represent mean expression±s.e.m. Statistical analyses in a,c,e and f were conducted by one-way ANOVA followed by Tukey's post hoc *P<0.05; **P<0.005; ***P<0.0005; NS, not significant.
Figure 6 Prkaca heterozygosity accelerates WNT-induced tumorigenesis. (a) Adrenal weight is significantly increased by loss of one Prkaca allele. Adrenal glands from wild-type, ΔCat;Akr1b7:Cre and ΔCat;Prkaca+/−;Akr1b7:Cre mice were weighed on killing. (b) Prkaca heterozygosity accelerates WNT-induced hyperplasia and dysplasia. ΔCat;Akr1b7:Cre (a) and ΔCat;Prkaca+/−;Akr1b7:Cre (b–d) adrenals were counterstained with haematoxylin and eosin. Pictures in b–d represent the range of phenotypes resulting from Prkaca heterozygosity. Scale bar, 400 μm. (c,d) Prkaca heterozygosity increases proliferation. Ki67 positive cells were counted in five high-power fields per adrenal (WT, n=3; ΔCat;Akr1b7:Cre, n=4; ΔCat;Prkaca+/−;Akr1b7:Cre, n=9).Results are expressed as a labelling index. Pictures in d show high-power fields for one ΔCat;Akr1b7:Cre adrenal (a) and three different ΔCat;Prkaca+/−;Akr1b7:Cre adrenals (b–d). (e) Prkaca heterozygosity is associated with increased malignancy. VegfA and Cnxa43 expression levels were analysed by RT–qPCR in wild-type (n=5), ΔCat;Akr1b7:Cre (n=7) and ΔCat;Prkaca+/−;Akr1b7:Cre (n=12) adrenals. (f,g) Prkaca heterozygosity increases WNT pathway activity. (f) Axin2 and Lef1 expression levels were analysed by RT–qPCR (g) LEF1 expression was analysed by immunohistochemistry in ΔCat;Akr1b7:Cre and ΔCat;Prkaca+/−;Akr1b7:Cre adrenals. Insets show ectopic accumulation of LEF1 within ZF. Scale bar, 100 μm. (h) Low StAR expression is associated with lower overall survival in ACC patients. The patients were separated as two equivalent groups of high (n=39) and low (n=40) StAR expression. Left panel: Kaplan–Meier estimates of overall survival. Right panel: patients were ordered by cut-off-centred StAR expression. Dark grey boxes indicate specific death. (i) WNT pathway activity is inversely correlated with StAR expression in ACC patients. Adrenocortical carcinoma patients with no mutation in CTNNB1, APC and ZNRF3 were selected and a WNT pathway activation signature was established based on expression levels of LEF1, AXIN2 and APCDD1. Left panel: Spearman correlation between WNT signature and StAR expression. Right panel: hierarchical clustering of patients as a function of StAR expression and corresponding levels of WNT gene signature and individual WNT target genes expression. Bars in e,f represent mean expression±s.e.m. Statistical analyses in a,c,e and f were conducted by one-way ANOVA followed by Tukey's post hoc *P<0.05; **P<0.005; ***P<0.0005; NS, not significant.CC BY · PubMed Central
Figure 7 Model for adrenocortical zonal differentiation. Left panel shows the zonal organization of the adrenal cortex with capsular (orange) and subcapsular (red) progenitor cells, ZG cells (purple), ZF cells (green) and transiting cells with double identity (purple and green). Solid blue arrows show the normal process of cell renewal occurring through recruitment of Shh-positive progenitors that initially differentiate as ZG cells and subsequently differentiate as ZF cells as they migrate within the cortex. Dashed arrows show alternative renewal pathways relying on capsular (Shh-negative) progenitors. Right panels show the interplay between WNT and PKA signalling pathways in ZG cells (purple) and ZF cells (green). Red arrows: activation; blue arrows: inhibition; grey arrows: inactive pathway.
Figure 7 Model for adrenocortical zonal differentiation. Left panel shows the zonal organization of the adrenal cortex with capsular (orange) and subcapsular (red) progenitor cells, ZG cells (purple), ZF cells (green) and transiting cells with double identity (purple and green). Solid blue arrows show the normal process of cell renewal occurring through recruitment of Shh-positive progenitors that initially differentiate as ZG cells and subsequently differentiate as ZF cells as they migrate within the cortex. Dashed arrows show alternative renewal pathways relying on capsular (Shh-negative) progenitors. Right panels show the interplay between WNT and PKA signalling pathways in ZG cells (purple) and ZF cells (green). Red arrows: activation; blue arrows: inhibition; grey arrows: inactive pathway.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

Items 101–128 of 128

Metadata

Authors
Drelon, C., Berthon, A., Sahut-Barnola, I., Mathieu, M., Dumontet, T., Rodriguez, S., Batisse-Lignier, M., Tabbal, H., Tauveron, I., Lefrançois-Martinez, A.-M., Pointud, J.-C., Gomez-Sanchez, C. E., Vainio, S., Shan, J., Sacco, S., Schedl, A., Stratakis, C. A., Martinez, A., & Val, P.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Infotech Oulu (FI)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
Corresponding author
Val, Pierre
Venue
Nature Communications
Published
2016-09-14
Volume
7
Issue
1
Pages
12751-12751
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2519501257
Cited by
128
References
50
Citations by year
2026: 12 · 2025: 11 · 2024: 11 · 2023: 15 · 2022: 13 · 2021: 17 · 2020: 10 · 2019: 17 · 2018: 11 · 2017: 9 · 2016: 1
FWCI
6.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Agence Nationale de la Recherche (ANR-14-CE12-0007)
  • Institut National de la Santé et de la Recherche Médicale (U1016)
  • Academy of Finland (20122017, 121647, 251314, 206038)
  • Fondation ARC pour la Recherche sur le Cancer
  • Ligue Contre le Cancer
  • Fondation de France
  • Centre National de la Recherche Scientifique (UMR8104)
  • FP7 Health (FP7/2007-2013, EURenOmics 305608, 305608)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
protein kinase A, Wnt signaling, Wnt4, adrenal cortex zonation, zona fasciculata, lineage conversion, β-catenin, adrenocortical carcinoma, tumour suppressor, aldosterone, glucocorticoids, cancer prognosis
MeSH terms
Adrenal Gland Neoplasms, Animals, Cell Differentiation, Female, Humans, Phosphorylation, Zona Fasciculata, Zona Glomerulosa, Cyclic AMP-Dependent Protein Kinases, Cell Line, Tumor, beta Catenin, Mice, Wnt Signaling Pathway, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.